Antibody design company
Appears in 1 story
New subsidiary focused on de novo antibody design; PROTEINA is largest shareholder
Artificial intelligence can design tens of thousands of antibody candidates in days. Turning those digital sequences into physical molecules for testing still takes months. PROTEINA and Twist Bioscience announced a partnership on August 27, 2026, to collapse that gap.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
